Jubilant Life Sciences is currently trading at Rs. 826.50, up by 3.15 points or 0.38% from its previous closing of Rs. 823.35 on the BSE.
The scrip opened at Rs. 823.45 and has touched a high and low of Rs. 834.85 and Rs. 821.45 respectively. So far 9527 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1039.00 on 08-Feb-2018 and a 52 week low of Rs. 600.00 on 25-Oct-2017.
Last one week high and low of the scrip stood at Rs. 880.00 and Rs. 820.00 respectively. The current market cap of the company is Rs. 13114.41 crore.
The promoters holding in the company stood at 50.68%, while Institutions and Non-Institutions held 29.04% and 20.28% respectively.
Jubilant Life Sciences’ material wholly owned subsidiary -- Jubilant Pharma, through one of its wholly owned subsidiaries (collectively Jubilant Life) has received Abbreviated New Drug Application (ANDA) final approval for Niacin Extended-Release Tablets USP, 500 mg, 750 mg, and 1,000 mg, the generic version of Niaspan of AbbVie, which is indicated to reduce elevated TC, LDL-C, Apo B and TG, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia thereby reducing the risk of recurrent nonfatal myocardial infarction in patients with a history of myocardial infarction and hyperlipidemia.
This is the first approval that the company has received from the USFDA during the current financial year. As on March 31, 2018, Jubilant had a total of 94 ANDAs for Oral Solids filed in the US, of which 59 had been approved and 12 Sterile (Injectables & Ophthlamics) filings, of which 10 had been approved.
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.
